Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739623 | 1.00 | KCNH2 (0.48) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6738998 | 0.95 | KCNH2 (0.51) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6738449 | 0.95 | KCNH2 (0.51) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6736864 | 0.95 | KCNH2 (0.51) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6734797 | 0.89 | KCNH2 (0.50) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6739387 | 0.89 | KCNH2 (0.50) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6742834 | 0.89 | KCNH2 (0.50) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6733478 | 0.89 | KCNH2 (0.44) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL7474790 | 0.88 | KCNH2 (0.47) | KCNH2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6739920 | 0.88 | MGLL (0.50) | KCNH2KDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1192157-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077000-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | KCNH2 13/4885KDM4E 4541/4885ALDH1A1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.